For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells.
The process is quick and effective, representing a pioneering contribution for applying direct reprogramming for inducing immunity. Importantly, the finding opens up the possibility of developing novel dendritic cell-based immunotherapies against cancer.
Our so-called dendritic cells function as the immune system’s sentinels. Their task is to scan our tissues for foreign particles, such as bacteria, viruses or cancer cells, and to devour them. They subsequently break down the particles into smaller pieces, known as antigens, and present them on the surface to the immune system’s killer cells (T-cells). In this way, the killer cells learn which infectious agents and cancer cells they are to search for and kill.
Due to these key features, dendritic cell-based strategies have been tested to treat cancer patients. However, cancer can affect the dendritic cells in such a way that they get lost or become dysfunctional. We therefore need to find new ways of generating dendritic cells for every patient. Now, for the first time, a research team in Lund has succeeded in obtaining dendritic cells by a process called direct reprogramming. They have identified three essential proteins (PU.1, IRF8 and BATF3) that are required and sufficient to change the identity of mouse cells to make them become dendritic cells instead. They have also confirmed that the same protein cocktail reprograms human skin-derived cells to dendritic cells. This study is now published and highlighted in the cover of the journal Science Immunology.
“From a tissue section taken from the skin, we can cultivate millions of cells and reprogram them to dendritic cells in a process that takes only nine days”, says Filipe Pereira, the leader of the research team that conducted the study.
“Our study has shown that reprogrammed cells have the ability to effectively capture and present antigens to killer cells in the same way as ‘natural’ dendritic cells.” The researchers can even direct the induced dendritic cells towards a particular target by presenting the right antigen to them in a test tube, before introducing the cells into the organism. This finding opens up future possibilities to develop new strategies for immunotherapy against solid tumours and blood cancers, beyond the treatments currently available.
“This represents an excellent opportunity to merge the fields of cellular reprogramming and cancer immunotherapy. Generating dendritic cells employing direct cell reprogramming is very attractive from a therapeutic perspective: our studies may be useful in the clinic for generation of patient-specific dendritic cells”, according to Filipe Pereira.
Cancer immunotherapy employs the cellular components of a persons’ immune system to fight cancer and it was awarded with the Nobel Prize in Physiology or Medicine this year. By using reprogrammed dendritic cells the probability of rejection by the organism is lower as these cells can be generated from the skin of each individual patient.
“Tumours often undergo a number of mutations, developing into a heterogeneous entity, which makes it more difficult for the immune system to identify them as a threat. In a more creative perspective, we now want to explore the process of dendritic cell reprogramming to develop a cancer gene therapy. We are aiming at injecting the three reprogramming proteins straight into the tumour forcing it to present their own tumour-specific antigens. This allows the activation of the killer cells against tumour cells and may lead to their elimination. We have named this concept TrojanDC in an analogy with Homero’s Trojan horse. The great potential of this technology for cancer treatment lead us to start a new company together with Lund University for the development of this concept into a product that hopefully will reach cancer patients one day”, says Filipe Pereira.
“Additionally, our studies open up the possibility of reprogramming other dendritic cell sub-types taking advantage of their distinct functional features. A better understanding of the mechanisms that determine the identity of immune sentinels and of how to use this knowledge to reprogram other cell types into dendritic cells could make these patient-specific cells useful in the clinic”, concludes Filipe Pereira.
Learn more: WATCH: A code for reprogramming immune sentinels
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Immunotherapies, personalised medicine and supportive care — cancer treatment is changingon November 22, 2020 at 11:54 pm
We look at what has happened in cancer care and research over the first two decades of the 21st century, a century which began with the first draft of the human genome and which promised all kinds of ...
- Five steps to improve access to cancer immunotherapieson November 22, 2020 at 9:10 pm
Immunotherapies are some of the most innovative new cancer treatments available to patients, but more needs to be done to get them to as many patients as possible. Policy Officer Aislinn Santoni looks ...
- Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodieson November 22, 2020 at 6:15 pm
DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French ...
- Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directorson November 20, 2020 at 5:42 am
Prof. June is a world authority on immune tolerance and adoptive immunotherapy. Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration. LAUSANNE, Switze ...
- Umoja banks $53M to develop triple-threat immunotherapieson November 18, 2020 at 11:32 pm
It decided to combine multiple technologies, designing them from the ground up to work together. Scharenberg sees immunotherapies as the future of cancer therapies because, in pediatrics, chemotherapy ...
- Immunotherapies effective against lung cancer, melanoma may also work against rare skin tumoron November 18, 2020 at 3:33 pm
Most skin cancers regress in response to inflammation and since immunotherapies that provoke an inflammatory response have proven successful in melanoma, immunotherapies targeted at non-melanoma ...
- Injectable cholesterol drug may boost cancer immunotherapies, Duke researchers sayon November 17, 2020 at 3:13 am
These cancer immunotherapies have held great promise, but still only result in long-term survival benefits for a third of cancer patients, at most. The study appears online Nov. 11 in the journal ...
- European Industry for Allergy Immunotherapies to 2027 - Growing Prevalence of Allergic Disorders is Driving Growthon November 13, 2020 at 6:18 am
For more information about this report visit https://www.researchandmarkets.com/r/gan7g0 ...
- European Industry for Allergy Immunotherapies to 2027 - Growing Prevalence of Allergic Disorders is Driving Growthon November 13, 2020 at 6:12 am
Disclaimer | Commerce Policy | Made In NYC | Stock quotes by finanzen.net DUBLIN, Nov. 13, 2020 /PRNewswire/ -- The "Europe Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and ...
via Bing News